US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Immix Biopharma, Inc.

8.15

-0.2100-2.51%

Post-market: 8.150.00000.00%16:10 EST

Volume:397.34K

Turnover:3.25M

Market Cap:431.58M

PE:-10.48

High:8.42

Open:8.26

Low:7.90

Close:8.36

52wk High:8.97

52wk Low:1.34

Shares:52.96M

Float Shares:41.44M

Volume Ratio:0.64

T/O Rate:0.96%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7776

EPS(LYR):-0.7641

ROE:-182.55%

ROA:-66.48%

PB:52.22

PE(LYR):-10.67

Loading ...

Overview Company News Filings

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS

Immix Biopharma Inc - Prices Offering of 19.12 Mln Shares at $5.10 per Share

THOMSON REUTERS

Immix Biopharma Reports 75% Complete Response Rate in Phase 2 NXC-201 Trial for Relapsed/Refractory AL Amyloidosis

at Ash 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 Nxc-201 Results, Advancing Toward Bla Submission as a Potentially First- and Best-in-Class Therapy for Relapsed/Refractory Al Amyloidosis

THOMSON REUTERS

Immix Biopharma Unveils Breakthrough Strategy for Relapsed/Refractory AL Amyloidosis

Immix Biopharma Appoints Michael Grabow as Chief Commercial Officer

Immix Biopharma Appoints Chief Commercial Officer to Drive Nxc-201 Launch

THOMSON REUTERS

Immix Biopharma Inc expected to post a loss of 17 cents a share - Earnings Preview

Immix Biopharma Unveils Breakthrough Approach for Relapsed AL Amyloidosis Treatment

Immix Biopharma to Present Phase 1/2 NXC-201 CAR-T Trial Results for AL Amyloidosis at ASH 2025

Immix Biopharma’s Nxc-201 Nexicart-2 Clinical Trial Results Selected for Oral Presentation at Ash 2025

THOMSON REUTERS

Immix Biopharma Inc. to Present at Guggenheim Healthcare Innovation Conference

Immix Biopharma Inc publishes presentation highlighting leadership in relapsed and refractory AL Amyloidosis and promising NXC201 clinical data

Immix Biopharma to Present Promising NXC-201 Clinical Study Results at 2025 ASH Annual Meeting

Immix Biopharma files to sell 6.85M shares of common stock for holders

Immix Biopharma Inc. to Present and Meet Investors at the 37th Annual Piper Sandler Healthcare Conference

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in Its Ongoing Relapsed/Refractory Al Amyloidosis Clinical Trial, Nexicart-2

THOMSON REUTERS

Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.

Immix Biopharma appoints Nancy Chang to board of directors

Nancy T. Chang, Renowned Biotechnology Leader, Joins Immix Biopharma Board of Directors as Company Strengthens Leadership Team

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMMX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMMX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMMX\",,,,,undefined,":{"symbol":"IMMX","market":"US","secType":"STK","nameCN":"Immix Biopharma, Inc.","latestPrice":8.15,"timestamp":1772571600000,"preClose":8.36,"halted":0,"volume":397341,"hourTrading":{"tag":"盘后","latestPrice":8.15,"preClose":8.15,"latestTime":"16:10 EST","volume":6254,"amount":50970.100000000006,"timestamp":1772572204649,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.025119617224880274,"floatShares":41439399,"shares":52955100,"eps":-0.777635,"marketStatus":"Post-Mkt","change":-0.21,"latestTime":"03-03 17:09:02 EST","open":8.26,"high":8.42,"low":7.9,"amount":3249155.787216,"amplitude":0.062201,"askPrice":8.45,"askSize":6,"bidPrice":7.9,"bidSize":82,"shortable":3,"etf":0,"ttmEps":-0.777635,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772586000000},"marketStatusCode":4,"adr":0,"listingDate":1639630800000,"exchange":"NASDAQ","adjPreClose":8.36,"preHourTrading":{"tag":"盘前","latestPrice":8.41,"preClose":8.36,"latestTime":"08:53 EST","volume":1830,"amount":15079.280519999998,"timestamp":1772546006727,"change":0.05,"changeRate":0.005981,"amplitude":0.033732},"postHourTrading":{"tag":"盘后","latestPrice":8.15,"preClose":8.15,"latestTime":"16:10 EST","volume":6254,"amount":50970.100000000006,"timestamp":1772572204649,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.64193,"impliedVol":1.1327,"impliedVolPercentile":0.4781},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMMX\",,,,,undefined,":{"symbol":"IMMX","floatShares":41439399,"roa":"-66.48%","roe":"-182.55%","lyrEps":-0.764111,"volumeRatio":0.64193,"shares":52955100,"dividePrice":0,"high":8.42,"amplitude":0.062201,"preClose":8.36,"low":7.9,"week52Low":1.34,"pbRate":"52.22","week52High":8.97,"institutionHeld":0,"latestPrice":8.15,"committee":0.863636,"eps":-0.777635,"divideRate":0,"volume":397341,"delay":0,"ttmEps":-0.777635,"open":8.26,"prevYearClose":5.23,"prevWeekClose":8.07,"prevMonthClose":8.07,"prevQuarterClose":5.23,"fiveDayClose":8.49,"twentyDayClose":6.21,"sixtyDayClose":4.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMMX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-07","symbol":"IMMX","fiscalQuarterEnding":"2025/09","expectedEps":-0.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"post","actualEps":-0.24},{"market":"US","date":"2025-08-08","symbol":"IMMX","fiscalQuarterEnding":"2025/06","expectedEps":-0.21,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754625600000,"reportTimeType":"post","actualEps":-0.22},{"market":"US","date":"2025-05-08","symbol":"IMMX","fiscalQuarterEnding":"2025/03","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2025-03-24","symbol":"IMMX","fiscalQuarterEnding":"2024/12","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"post","actualEps":-0.16},{"market":"US","date":"2024-11-12","symbol":"IMMX","fiscalQuarterEnding":"2024/09","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":-0.24}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMMX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IMMX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1770872400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IMMX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IMMX","date":"2026-03-02","current":-10.750545,"percent":0.04466,"low":-37.240428,"twenty":-5.916977,"median":-2.966167,"eighty":-1.366055,"high":-0.384227,"avg":-4.773527,"sd":5.522529,"marketCap":425252838},"quantilePoints":[{"date":"2021-12-17","current":-22.068402,"twenty":-20.976016,"median":-17.642249,"eighty":-15.03674,"marketCap":52834756},{"date":"2021-12-23","current":-16.275446,"twenty":-19.828459,"median":-17.958163,"eighty":-15.532222,"marketCap":38965632},{"date":"2021-12-31","current":-19.640878,"twenty":-19.806391,"median":-18.096089,"eighty":-16.937498,"marketCap":47022932},{"date":"2022-01-07","current":-29.461317,"twenty":-29.957856,"median":-19.420194,"eighty":-17.952645,"marketCap":70534399},{"date":"2022-01-14","current":-32.219867,"twenty":-32.197799,"median":-20.247759,"eighty":-17.985748,"marketCap":77138743},{"date":"2022-01-21","current":-24.882123,"twenty":-32.142628,"median":-24.882123,"eighty":-18.007816,"marketCap":59571187},{"date":"2022-01-28","current":-21.461521,"twenty":-32.021251,"median":-22.399428,"eighty":-18.140226,"marketCap":51381800},{"date":"2022-02-04","current":-24.109729,"twenty":-31.756431,"median":-22.399428,"eighty":-18.493321,"marketCap":57721970},{"date":"2022-02-11","current":-23.282164,"twenty":-31.039208,"median":-23.30975,"eighty":-19.276749,"marketCap":55740667},{"date":"2022-02-18","current":-19.75122,"twenty":-30.222677,"median":-22.399428,"eighty":-19.59674,"marketCap":47287106},{"date":"2022-02-25","current":-17.654721,"twenty":-29.957856,"median":-22.123573,"eighty":-18.096089,"marketCap":42267804},{"date":"2022-03-04","current":-11.641082,"twenty":-29.902685,"median":-21.875304,"eighty":-17.875406,"marketCap":27870333},{"date":"2022-03-11","current":-10.261807,"twenty":-29.461317,"median":-21.461521,"eighty":-16.440959,"marketCap":24568161},{"date":"2022-03-18","current":-13.296212,"twenty":-27.199305,"median":-20.771884,"eighty":-15.03674,"marketCap":31832940},{"date":"2022-03-25","current":-11.751424,"twenty":-26.592424,"median":-19.75122,"eighty":-13.241041,"marketCap":28134507},{"date":"2022-04-01","current":-1.409519,"twenty":-26.482082,"median":-19.392608,"eighty":-11.751424,"marketCap":34369548},{"date":"2022-04-08","current":-1.028722,"twenty":-25.433833,"median":-18.096089,"eighty":-11.254885,"marketCap":25084227},{"date":"2022-04-14","current":-1.023038,"twenty":-24.992465,"median":-17.985748,"eighty":-10.416286,"marketCap":24945640},{"date":"2022-04-22","current":-0.818431,"twenty":-24.264208,"median":-17.765064,"eighty":-1.459534,"marketCap":19956512},{"date":"2022-04-29","current":-0.785819,"twenty":-24.109729,"median":-17.047841,"eighty":-1.310625,"marketCap":19161305},{"date":"2022-05-06","current":-0.848456,"twenty":-23.491814,"median":-15.778907,"eighty":-1.093514,"marketCap":20688655},{"date":"2022-05-13","current":-0.733622,"twenty":-23.293198,"median":-15.03674,"eighty":-0.9878,"marketCap":18119930},{"date":"2022-05-20","current":-1.191784,"twenty":-22.840796,"median":-13.351383,"eighty":-0.962793,"marketCap":29436208},{"date":"2022-05-27","current":-1.506595,"twenty":-22.465633,"median":-12.854844,"eighty":-0.975297,"marketCap":37211810},{"date":"2022-06-03","current":-1.394163,"twenty":-22.30012,"median":-12.247963,"eighty":-0.98098,"marketCap":34434809},{"date":"2022-06-10","current":-1.366055,"twenty":-22.16771,"median":-11.696253,"eighty":-0.986663,"marketCap":33740559},{"date":"2022-06-17","current":-1.366055,"twenty":-22.09047,"median":-11.254885,"eighty":-1.009398,"marketCap":33740559},{"date":"2022-06-24","current":-1.197406,"twenty":-22.046334,"median":-10.482491,"eighty":-1.025312,"marketCap":29575058},{"date":"2022-07-01","current":-1.461622,"twenty":-21.902889,"median":-10.344563,"eighty":-1.033234,"marketCap":36101010},{"date":"2022-07-08","current":-1.506595,"twenty":-21.737376,"median":-5.965715,"eighty":-1.047976,"marketCap":37211810},{"date":"2022-07-15","current":-1.534704,"twenty":-21.682205,"median":-1.669623,"eighty":-1.083284,"marketCap":37906060},{"date":"2022-07-22","current":-1.377298,"twenty":-21.461521,"median":-1.540325,"eighty":-1.107154,"marketCap":34018259},{"date":"2022-07-29","current":-1.371676,"twenty":-21.428418,"median":-1.529082,"eighty":-1.149213,"marketCap":33879409},{"date":"2022-08-05","current":-1.414851,"twenty":-21.086358,"median":-1.509406,"eighty":-1.161365,"marketCap":34945778},{"date":"2022-08-12","current":-1.308074,"twenty":-20.181554,"median":-1.484109,"eighty":-1.191784,"marketCap":34079789},{"date":"2022-08-19","current":-1.073155,"twenty":-19.88363,"median":-1.475262,"eighty":-1.182306,"marketCap":27959337},{"date":"2022-08-26","current":-1.09985,"twenty":-19.729152,"median":-1.461622,"eighty":-1.149213,"marketCap":28654843},{"date":"2022-09-02","current":-1.035781,"twenty":-19.629844,"median":-1.425082,"eighty":-1.094994,"marketCap":26985628},{"date":"2022-09-09","current":-0.961034,"twenty":-19.585706,"median":-1.416649,"eighty":-1.051798,"marketCap":25038212},{"date":"2022-09-16","current":-0.977051,"twenty":-19.19951,"median":-1.413839,"eighty":-1.023038,"marketCap":25455515},{"date":"2022-09-23","current":-0.787514,"twenty":-18.316774,"median":-1.407462,"eighty":-0.983253,"marketCap":20517424},{"date":"2022-09-30","current":-0.726114,"twenty":-18.096089,"median":-1.388541,"eighty":-0.966203,"marketCap":18917760},{"date":"2022-10-07","current":-0.69408,"twenty":-17.985748,"median":-1.380109,"eighty":-0.928999,"marketCap":18083153},{"date":"2022-10-14","current":-0.646028,"twenty":-17.985748,"median":-1.371676,"eighty":-0.916325,"marketCap":16831242},{"date":"2022-10-21","current":-0.630011,"twenty":-17.930577,"median":-1.366055,"eighty":-0.871234,"marketCap":16413939},{"date":"2022-10-28","current":-0.573951,"twenty":-17.875406,"median":-1.366055,"eighty":-0.854252,"marketCap":14953376},{"date":"2022-11-04","current":-0.485856,"twenty":-17.654721,"median":-1.352001,"eighty":-0.819985,"marketCap":12658207},{"date":"2022-11-11","current":-0.448265,"twenty":-17.213353,"median":-1.343568,"eighty":-0.800862,"marketCap":12186169},{"date":"2022-11-18","current":-0.665994,"twenty":-17.047841,"median":-1.333979,"eighty":-0.785819,"marketCap":18105187},{"date":"2022-11-25","current":-0.686486,"twenty":-16.562335,"median":-1.321082,"eighty":-0.77203,"marketCap":18662269},{"date":"2022-12-02","current":-0.588739,"twenty":-16.308549,"median":-1.309839,"eighty":-0.750858,"marketCap":16004985},{"date":"2022-12-09","current":-0.712102,"twenty":-15.480984,"median":-1.267676,"eighty":-0.736159,"marketCap":19358623},{"date":"2022-12-16","current":-0.968253,"twenty":-15.085866,"median":-1.244005,"eighty":-0.741064,"marketCap":26322156},{"date":"2022-12-23","current":-1.111698,"twenty":-15.03674,"median":-1.214271,"eighty":-0.746567,"marketCap":30221735},{"date":"2022-12-30","current":-1.173175,"twenty":-14.853091,"median":-1.211283,"eighty":-0.747676,"marketCap":31892983},{"date":"2023-01-06","current":-1.19879,"twenty":-14.201016,"median":-1.209622,"eighty":-0.747791,"marketCap":32589336},{"date":"2023-01-13","current":-1.127067,"twenty":-13.362417,"median":-1.203028,"eighty":-0.749439,"marketCap":30639547},{"date":"2023-01-20","current":-1.101452,"twenty":-13.285178,"median":-1.197406,"eighty":-0.751884,"marketCap":29943194},{"date":"2023-01-27","current":-1.229528,"twenty":-13.163802,"median":-1.200909,"eighty":-0.753717,"marketCap":33424960},{"date":"2023-02-03","current":-1.608632,"twenty":-12.744502,"median":-1.208649,"eighty":-0.758575,"marketCap":43730990},{"date":"2023-02-10","current":-1.357604,"twenty":-12.2921,"median":-1.211283,"eighty":-0.764481,"marketCap":36906727},{"date":"2023-02-17","current":-1.173175,"twenty":-12.148655,"median":-1.210595,"eighty":-0.769597,"marketCap":31892983},{"date":"2023-02-24","current":-1.101452,"twenty":-11.751424,"median":-1.203913,"eighty":-0.774166,"marketCap":29943194},{"date":"2023-03-03","current":-1.075837,"twenty":-11.751424,"median":-1.198098,"eighty":-0.77443,"marketCap":29246840},{"date":"2023-03-10","current":-0.922146,"twenty":-11.641082,"median":-1.191784,"eighty":-0.785819,"marketCap":25068720},{"date":"2023-03-17","current":-0.932392,"twenty":-11.365227,"median":-1.185983,"eighty":-0.785819,"marketCap":25347261},{"date":"2023-03-24","current":-0.935614,"twenty":-11.254885,"median":-1.179936,"eighty":-0.787514,"marketCap":25434844},{"date":"2023-03-31","current":-3.073723,"twenty":-10.915583,"median":-1.185983,"eighty":-0.791513,"marketCap":25295856},{"date":"2023-04-06","current":-2.938614,"twenty":-10.569109,"median":-1.191784,"eighty":-0.796068,"marketCap":24183950},{"date":"2023-04-14","current":-2.98928,"twenty":-10.438354,"median":-1.197406,"eighty":-0.800131,"marketCap":24600914},{"date":"2023-04-21","current":-3.175054,"twenty":-10.383183,"median":-1.20347,"eighty":-0.807049,"marketCap":26129785},{"date":"2023-04-28","current":-3.884375,"twenty":-10.328012,"median":-1.210595,"eighty":-0.808596,"marketCap":31967290},{"date":"2023-05-05","current":-4.576322,"twenty":-10.272841,"median":-1.214215,"eighty":-0.816464,"marketCap":37661819},{"date":"2023-05-11","current":-3.813602,"twenty":-7.053908,"median":-1.216776,"eighty":-0.819363,"marketCap":31384849},{"date":"2023-05-19","current":-2.841134,"twenty":-4.874631,"median":-1.234651,"eighty":-0.836103,"marketCap":26642250},{"date":"2023-05-26","current":-2.380008,"twenty":-4.766155,"median":-1.244451,"eighty":-0.847813,"marketCap":22318115},{"date":"2023-06-02","current":-3.190234,"twenty":-4.657679,"median":-1.251483,"eighty":-0.848456,"marketCap":29915874},{"date":"2023-06-09","current":-3.254359,"twenty":-4.562763,"median":-1.270512,"eighty":-0.850774,"marketCap":30517199},{"date":"2023-06-16","current":-3.783393,"twenty":-4.400049,"median":-1.307224,"eighty":-0.856388,"marketCap":35478123},{"date":"2023-06-23","current":-4.10402,"twenty":-4.223113,"median":-1.309839,"eighty":-0.860781,"marketCap":38484743},{"date":"2023-06-30","current":-4.376552,"twenty":-4.23227,"median":-1.321082,"eighty":-0.865539,"marketCap":41040371},{"date":"2023-07-07","current":-4.152114,"twenty":-4.486677,"median":-1.332157,"eighty":-0.869324,"marketCap":38935736},{"date":"2023-07-14","current":-3.735299,"twenty":-4.39579,"median":-1.337947,"eighty":-0.871041,"marketCap":35027129},{"date":"2023-07-21","current":-3.572376,"twenty":-4.261126,"median":-1.345284,"eighty":-0.89609,"marketCap":33499345},{"date":"2023-07-28","current":-3.503009,"twenty":-4.195644,"median":-1.34919,"eighty":-0.905882,"marketCap":32848872},{"date":"2023-08-04","current":-3.503009,"twenty":-4.184638,"median":-1.356208,"eighty":-0.90747,"marketCap":32848872},{"date":"2023-08-11","current":-3.29491,"twenty":-4.158526,"median":-1.366055,"eighty":-0.911914,"marketCap":30897454},{"date":"2023-08-18","current":-2.330617,"twenty":-4.113639,"median":-1.367895,"eighty":-0.915656,"marketCap":26547513},{"date":"2023-08-25","current":-2.916846,"twenty":-4.034399,"median":-1.377298,"eighty":-0.920982,"marketCap":33225108},{"date":"2023-09-01","current":-2.902547,"twenty":-3.980385,"median":-1.38292,"eighty":-0.922146,"marketCap":33062240},{"date":"2023-09-08","current":-3.560267,"twenty":-3.968181,"median":-1.391352,"eighty":-0.923054,"marketCap":40554176},{"date":"2023-09-15","current":-3.631759,"twenty":-3.972707,"median":-1.409519,"eighty":-0.92366,"marketCap":41368517},{"date":"2023-09-22","current":-4.932901,"twenty":-4.034479,"median":-1.414345,"eighty":-0.926863,"marketCap":56189522},{"date":"2023-09-29","current":-6.358344,"twenty":-4.1851,"median":-1.416649,"eighty":-0.928999,"marketCap":72426414},{"date":"2023-10-06","current":-6.479291,"twenty":-4.315729,"median":-1.429506,"eighty":-0.931035,"marketCap":73804091},{"date":"2023-10-13","current":-5.615385,"twenty":-4.616006,"median":-1.461622,"eighty":-0.934325,"marketCap":63963545},{"date":"2023-10-20","current":-4.872427,"twenty":-4.777335,"median":-1.471175,"eighty":-0.943737,"marketCap":55500676},{"date":"2023-10-27","current":-6.375622,"twenty":-4.847512,"median":-1.475262,"eighty":-0.949152,"marketCap":72623225},{"date":"2023-11-03","current":-6.064616,"twenty":-4.932901,"median":-1.484109,"eighty":-0.950356,"marketCap":69080629},{"date":"2023-11-10","current":-6.410178,"twenty":-5.131598,"median":-1.509406,"eighty":-0.958007,"marketCap":73016847},{"date":"2023-11-17","current":-6.195423,"twenty":-5.719054,"median":-1.529082,"eighty":-0.961034,"marketCap":87580854},{"date":"2023-11-24","current":-6.703742,"twenty":-5.892712,"median":-1.540325,"eighty":-0.965169,"marketCap":94766658},{"date":"2023-12-01","current":-7.181577,"twenty":-6.076855,"median":-1.603509,"eighty":-0.967843,"marketCap":101521514},{"date":"2023-12-08","current":-7.01293,"twenty":-6.195898,"median":-1.669623,"eighty":-0.968253,"marketCap":99137447},{"date":"2023-12-15","current":-7.982654,"twenty":-6.218411,"median":-2.022607,"eighty":-0.97102,"marketCap":112845832},{"date":"2023-12-22","current":-10.034533,"twenty":-6.379078,"median":-2.409758,"eighty":-0.973043,"marketCap":141851979},{"date":"2023-12-29","current":-9.430212,"twenty":-6.451646,"median":-2.432071,"eighty":-0.974846,"marketCap":133309073},{"date":"2024-01-05","current":-8.50265,"twenty":-6.565681,"median":-2.473599,"eighty":-0.977051,"marketCap":120196705},{"date":"2024-01-12","current":-8.685352,"twenty":-6.703742,"median":-2.585988,"eighty":-0.97757,"marketCap":122779444},{"date":"2024-01-19","current":-7.518873,"twenty":-6.911741,"median":-2.60785,"eighty":-0.978313,"marketCap":106289648},{"date":"2024-01-26","current":-5.256184,"twenty":-7.018552,"median":-2.655395,"eighty":-0.982302,"marketCap":74303417},{"date":"2024-02-02","current":-5.466993,"twenty":-6.911741,"median":-2.795833,"eighty":-0.986834,"marketCap":77283501},{"date":"2024-02-09","current":-5.804128,"twenty":-6.774012,"median":-2.816758,"eighty":-0.987729,"marketCap":82049361},{"date":"2024-02-16","current":-5.229106,"twenty":-6.712174,"median":-2.843244,"eighty":-0.988695,"marketCap":73920631},{"date":"2024-02-23","current":-5.498647,"twenty":-6.703742,"median":-2.873951,"eighty":-0.994969,"marketCap":77730973},{"date":"2024-03-01","current":-6.019761,"twenty":-6.693474,"median":-2.904837,"eighty":-1.003911,"marketCap":85097634},{"date":"2024-03-08","current":-6.073669,"twenty":-6.663866,"median":-2.910842,"eighty":-1.008419,"marketCap":85859703},{"date":"2024-03-15","current":-5.10332,"twenty":-6.640353,"median":-2.938614,"eighty":-1.009238,"marketCap":72142472},{"date":"2024-03-22","current":-5.462708,"twenty":-6.634794,"median":-2.972392,"eighty":-1.015386,"marketCap":77222928},{"date":"2024-03-28","current":-5.516617,"twenty":-6.623022,"median":-3.014613,"eighty":-1.020906,"marketCap":77984996},{"date":"2024-04-05","current":-4.808357,"twenty":-6.594122,"median":-3.042817,"eighty":-1.023666,"marketCap":74173940},{"date":"2024-04-12","current":-4.945249,"twenty":-6.572627,"median":-3.073723,"eighty":-1.026253,"marketCap":76285653},{"date":"2024-04-19","current":-3.781661,"twenty":-6.536582,"median":-3.124388,"eighty":-1.031174,"marketCap":58336088},{"date":"2024-04-26","current":-3.593434,"twenty":-6.487476,"median":-3.158168,"eighty":-1.035224,"marketCap":55432482},{"date":"2024-05-03","current":-3.953922,"twenty":-6.475173,"median":-3.175054,"eighty":-1.037469,"marketCap":60993385},{"date":"2024-05-10","current":-3.731407,"twenty":-6.445469,"median":-3.190234,"eighty":-1.04472,"marketCap":57560857},{"date":"2024-05-17","current":-3.263275,"twenty":-6.403267,"median":-3.190234,"eighty":-1.053237,"marketCap":59409141},{"date":"2024-05-24","current":-3.07473,"twenty":-6.385989,"median":-3.190496,"eighty":-1.057425,"marketCap":55976613},{"date":"2024-05-31","current":-3.03122,"twenty":-6.372166,"median":-3.190496,"eighty":-1.060468,"marketCap":55184491},{"date":"2024-06-07","current":-2.988868,"twenty":-6.351433,"median":-3.175054,"eighty":-1.060468,"marketCap":54413458},{"date":"2024-06-14","current":-3.017886,"twenty":-6.323788,"median":-3.168385,"eighty":-1.060468,"marketCap":54941744},{"date":"2024-06-21","current":-2.785741,"twenty":-6.296199,"median":-3.161751,"eighty":-1.064566,"marketCap":50715456},{"date":"2024-06-28","current":-3.090431,"twenty":-6.282377,"median":-3.158171,"eighty":-1.065591,"marketCap":56262459},{"date":"2024-07-05","current":-3.554721,"twenty":-6.254675,"median":-3.158171,"eighty":-1.065591,"marketCap":64715035},{"date":"2024-07-12","current":-2.916322,"twenty":-6.209345,"median":-3.158168,"eighty":-1.070714,"marketCap":53092743},{"date":"2024-07-15","current":-3.061413,"twenty":-6.207036,"median":-3.158166,"eighty":-1.071202,"marketCap":55734173},{"date":"2024-08-02","current":-3.017886,"twenty":-6.204727,"median":-3.149722,"eighty":-1.07169,"marketCap":54941744},{"date":"2024-08-09","current":-2.901813,"twenty":-6.196849,"median":-3.133958,"eighty":-1.074228,"marketCap":52828600},{"date":"2024-08-16","current":-2.727429,"twenty":-6.184568,"median":-3.121919,"eighty":-1.075837,"marketCap":51881405},{"date":"2024-08-23","current":-3.189215,"twenty":-6.151983,"median":-3.124388,"eighty":-1.077452,"marketCap":60665558},{"date":"2024-08-30","current":-3.059338,"twenty":-6.126842,"median":-3.121919,"eighty":-1.082358,"marketCap":58195015},{"date":"2024-09-06","current":-3.030476,"twenty":-6.115383,"median":-3.11765,"eighty":-1.08762,"marketCap":57646005},{"date":"2024-09-13","current":-2.616311,"twenty":-6.073669,"median":-3.10494,"eighty":-1.093836,"marketCap":49767718},{"date":"2024-09-20","current":-2.554258,"twenty":-6.071858,"median":-3.096621,"eighty":-1.094187,"marketCap":48587347},{"date":"2024-09-27","current":-2.294503,"twenty":-6.055645,"median":-3.0882,"eighty":-1.094875,"marketCap":43646261},{"date":"2024-10-04","current":-1.933732,"twenty":-6.018828,"median":-3.074226,"eighty":-1.096448,"marketCap":36783641},{"date":"2024-10-11","current":-1.991456,"twenty":-6.007724,"median":-3.06426,"eighty":-1.097509,"marketCap":37881661},{"date":"2024-10-18","current":-2.438812,"twenty":-5.972157,"median":-3.060376,"eighty":-1.10017,"marketCap":46391309},{"date":"2024-10-25","current":-2.294503,"twenty":-5.941702,"median":-3.03122,"eighty":-1.101452,"marketCap":43646261},{"date":"2024-10-31","current":-2.381088,"twenty":-5.916977,"median":-3.023057,"eighty":-1.101452,"marketCap":45293290},{"date":"2024-11-08","current":-2.525397,"twenty":-5.911944,"median":-3.017886,"eighty":-1.101452,"marketCap":48038338},{"date":"2024-11-15","current":-2.035664,"twenty":-5.909113,"median":-3.016045,"eighty":-1.101452,"marketCap":44562371},{"date":"2024-11-22","current":-2.111059,"twenty":-5.888612,"median":-2.996328,"eighty":-1.106575,"marketCap":46212830},{"date":"2024-11-29","current":-2.65139,"twenty":-5.866126,"median":-2.988868,"eighty":-1.110673,"marketCap":58041114},{"date":"2024-12-06","current":-3.166589,"twenty":-5.85853,"median":-2.974359,"eighty":-1.111698,"marketCap":69319245},{"date":"2024-12-13","current":-2.676521,"twenty":-5.85743,"median":-2.967105,"eighty":-1.123993,"marketCap":58591266},{"date":"2024-12-20","current":-2.789614,"twenty":-5.829133,"median":-2.955503,"eighty":-1.127067,"marketCap":61066954},{"date":"2024-12-27","current":-2.638824,"twenty":-5.811316,"median":-2.943891,"eighty":-1.127067,"marketCap":57766037},{"date":"2025-01-03","current":-2.764482,"twenty":-5.804128,"median":-2.938614,"eighty":-1.127067,"marketCap":60516801},{"date":"2025-01-10","current":-2.827311,"twenty":-5.790569,"median":-2.938614,"eighty":-1.129098,"marketCap":61892183},{"date":"2025-01-17","current":-2.588561,"twenty":-5.735516,"median":-2.916584,"eighty":-1.137241,"marketCap":56665732},{"date":"2025-01-24","current":-2.575995,"twenty":-5.73225,"median":-2.915797,"eighty":-1.137313,"marketCap":56390655},{"date":"2025-01-31","current":-2.475468,"twenty":-5.73225,"median":-2.904837,"eighty":-1.137313,"marketCap":54190044},{"date":"2025-02-07","current":-2.538297,"twenty":-5.719054,"median":-2.903771,"eighty":-1.147559,"marketCap":55565426},{"date":"2025-02-14","current":-2.5006,"twenty":-5.615385,"median":-2.901813,"eighty":-1.148076,"marketCap":54740197},{"date":"2025-02-21","current":-2.236717,"twenty":-5.579497,"median":-2.888249,"eighty":-1.152623,"marketCap":48963593},{"date":"2025-02-28","current":-1.985401,"twenty":-5.541774,"median":-2.868902,"eighty":-1.165176,"marketCap":43462066},{"date":"2025-03-07","current":-2.073362,"twenty":-5.534586,"median":-2.845354,"eighty":-1.172146,"marketCap":45387601},{"date":"2025-03-14","current":-1.985401,"twenty":-5.520211,"median":-2.842004,"eighty":-1.173175,"marketCap":43462066},{"date":"2025-03-21","current":-2.286981,"twenty":-5.502241,"median":-2.829268,"eighty":-1.174313,"marketCap":50063899},{"date":"2025-03-28","current":-2.193309,"twenty":-5.498647,"median":-2.816758,"eighty":-1.178868,"marketCap":47404804},{"date":"2025-04-04","current":-2.026566,"twenty":-5.473324,"median":-2.814746,"eighty":-1.182724,"marketCap":43800930},{"date":"2025-04-11","current":-1.876497,"twenty":-5.463565,"median":-2.796559,"eighty":-1.183421,"marketCap":40557444},{"date":"2025-04-17","current":-2.01374,"twenty":-5.462708,"median":-2.786951,"eighty":-1.186495,"marketCap":43523709},{"date":"2025-04-25","current":-2.244614,"twenty":-5.451927,"median":-2.764482,"eighty":-1.190488,"marketCap":48513689},{"date":"2025-05-02","current":-2.616579,"twenty":-5.433958,"median":-2.746872,"eighty":-1.191784,"marketCap":56553100},{"date":"2025-05-09","current":-2.751256,"twenty":-5.40031,"median":-2.741859,"eighty":-1.192914,"marketCap":59463921},{"date":"2025-05-16","current":-2.77262,"twenty":-5.376785,"median":-2.741859,"eighty":-1.19591,"marketCap":57939205},{"date":"2025-05-23","current":-3.215034,"twenty":-5.372861,"median":-2.751256,"eighty":-1.198236,"marketCap":67184276},{"date":"2025-05-30","current":-3.001587,"twenty":-5.371163,"median":-2.741859,"eighty":-1.200485,"marketCap":62723909},{"date":"2025-06-06","current":-2.921545,"twenty":-5.340508,"median":-2.75157,"eighty":-1.203382,"marketCap":61051271},{"date":"2025-06-13","current":-3.321757,"twenty":-5.292213,"median":-2.764482,"eighty":-1.205807,"marketCap":69414459},{"date":"2025-06-20","current":-3.185499,"twenty":-5.277648,"median":-2.77262,"eighty":-1.209038,"marketCap":66567094},{"date":"2025-06-27","current":-2.985572,"twenty":-5.250768,"median":-2.77262,"eighty":-1.21087,"marketCap":62389243},{"date":"2025-07-03","current":-3.398754,"twenty":-5.229106,"median":-2.77918,"eighty":-1.211971,"marketCap":71023469},{"date":"2025-07-11","current":-3.615245,"twenty":-5.199968,"median":-2.789614,"eighty":-1.214159,"marketCap":75547464},{"date":"2025-07-18","current":-3.891907,"twenty":-5.183433,"median":-2.801329,"eighty":-1.214271,"marketCap":81328835},{"date":"2025-07-25","current":-3.718637,"twenty":-5.157515,"median":-2.814746,"eighty":-1.214271,"marketCap":77708031},{"date":"2025-08-01","current":-3.625338,"twenty":-5.131598,"median":-2.81579,"eighty":-1.219282,"marketCap":75758367},{"date":"2025-08-08","current":-3.185499,"twenty":-5.10332,"median":-2.827311,"eighty":-1.229528,"marketCap":66567094},{"date":"2025-08-15","current":-2.730486,"twenty":-5.097042,"median":-2.829268,"eighty":-1.234651,"marketCap":63146703},{"date":"2025-08-22","current":-2.842698,"twenty":-5.08535,"median":-2.829268,"eighty":-1.239774,"marketCap":65741773},{"date":"2025-08-29","current":-2.855166,"twenty":-5.05541,"median":-2.828289,"eighty":-1.244005,"marketCap":66030114},{"date":"2025-09-05","current":-2.730486,"twenty":-5.050611,"median":-2.822035,"eighty":-1.244719,"marketCap":63146703},{"date":"2025-09-12","current":-3.135663,"twenty":-5.041037,"median":-2.829268,"eighty":-1.248455,"marketCap":72517025},{"date":"2025-09-19","current":-2.952043,"twenty":-5.032845,"median":-2.829268,"eighty":-1.252766,"marketCap":68270533},{"date":"2025-09-26","current":-2.88142,"twenty":-5.021216,"median":-2.841134,"eighty":-1.258937,"marketCap":66637267},{"date":"2025-10-03","current":-2.966167,"twenty":-4.985765,"median":-2.842786,"eighty":-1.268463,"marketCap":68597186},{"date":"2025-10-10","current":-3.644148,"twenty":-4.976383,"median":-2.845354,"eighty":-1.279486,"marketCap":84276543},{"date":"2025-10-17","current":-3.813644,"twenty":-4.96287,"median":-2.862331,"eighty":-1.301444,"marketCap":88196382},{"date":"2025-10-24","current":-4.84474,"twenty":-4.948112,"median":-2.867634,"eighty":-1.307734,"marketCap":112042071},{"date":"2025-10-31","current":-5.18373,"twenty":-4.985765,"median":-2.87798,"eighty":-1.309486,"marketCap":119881750},{"date":"2025-11-07","current":-4.279756,"twenty":-5.021216,"median":-2.888249,"eighty":-1.309839,"marketCap":98975940},{"date":"2025-11-14","current":-5.144377,"twenty":-5.032845,"median":-2.892422,"eighty":-1.318833,"marketCap":121216121},{"date":"2025-11-21","current":-5.728642,"twenty":-5.087688,"median":-2.895544,"eighty":-1.321082,"marketCap":134983049},{"date":"2025-11-28","current":-6.0564,"twenty":-5.114631,"median":-2.902547,"eighty":-1.327626,"marketCap":142705960},{"date":"2025-12-05","current":-6.897171,"twenty":-5.157243,"median":-2.904837,"eighty":-1.332191,"marketCap":162516905},{"date":"2025-12-12","current":-10.51676,"twenty":-5.211623,"median":-2.904928,"eighty":-1.33431,"marketCap":247804702},{"date":"2025-12-19","current":-8.136951,"twenty":-5.289147,"median":-2.91247,"eighty":-1.337021,"marketCap":191729654},{"date":"2025-12-26","current":-12.836836,"twenty":-5.371163,"median":-2.916322,"eighty":-1.338637,"marketCap":302472279},{"date":"2026-01-02","current":-11.696281,"twenty":-5.41795,"median":-2.917888,"eighty":-1.340452,"marketCap":275597564},{"date":"2026-01-09","current":-11.383187,"twenty":-5.466136,"median":-2.921725,"eighty":-1.344254,"marketCap":268220191},{"date":"2026-01-16","current":-10.533362,"twenty":-5.515013,"median":-2.937918,"eighty":-1.347072,"marketCap":248195894},{"date":"2026-01-23","current":-11.741009,"twenty":-5.570525,"median":-2.938614,"eighty":-1.347358,"marketCap":276651474},{"date":"2026-01-30","current":-13.306477,"twenty":-5.728642,"median":-2.945341,"eighty":-1.34919,"marketCap":313538338},{"date":"2026-02-06","current":-13.306477,"twenty":-5.742892,"median":-2.952043,"eighty":-1.354812,"marketCap":313538338},{"date":"2026-02-13","current":-16.616323,"twenty":-5.822097,"median":-2.95297,"eighty":-1.354812,"marketCap":391527706},{"date":"2026-02-20","current":-17.466148,"twenty":-5.866126,"median":-2.95985,"eighty":-1.357046,"marketCap":411552003},{"date":"2026-02-27","current":-18.986888,"twenty":-5.914512,"median":-2.965852,"eighty":-1.364365,"marketCap":447384956},{"date":"2026-03-02","current":-18.047608,"twenty":-5.916977,"median":-2.966167,"eighty":-1.366055,"marketCap":425252838}],"updateTime":1772534875898},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMMX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2589856801","title":"Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2589856801","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589856801?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:20","pubTimestamp":1765149602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nTUA408RKK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2589801855","title":"Immix Biopharma Inc - Prices Offering of 19.12 Mln  Shares  at $5.10 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801855","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589801855?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:20","pubTimestamp":1765149602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nTUA408RKK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2589809706","title":"Immix Biopharma Reports 75% Complete Response Rate in Phase 2 NXC-201 Trial for Relapsed/Refractory AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2589809706","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589809706?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:15","pubTimestamp":1765149317,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on December 07, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL9YT2sp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX","LU2095319765.USD","LU2210149790.SGD","SG9999014013.SGD","IE00BKPKM429.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4112","SG9999014005.SGD","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","SG9999014021.USD","NDAQ","IE00B64PRP62.GBP","BK4588"],"gpt_icon":0},{"id":"2589809766","title":"at Ash 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 Nxc-201 Results, Advancing Toward Bla Submission as a Potentially First- and Best-in-Class Therapy for Relapsed/Refractory Al Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2589809766","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589809766?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:15","pubTimestamp":1765149300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nTUA3KCQML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2588057172","title":"Immix Biopharma Unveils Breakthrough Strategy for Relapsed/Refractory AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2588057172","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588057172?lang=en_us&edition=fundamental","pubTime":"2025-12-03 00:44","pubTimestamp":1764693877,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc. has released a presentation highlighting the challenges faced by patients with relapsed or refractory AL amyloidosis in the United States. The document reports that approximately 38,500 US patients are affected by this rare disease, which involves the accumulation of toxic light chains that damage major organs such as the heart, kidneys, and liver. The presentation notes that there are currently no FDA-approved therapies for patients who relapse after first-line treatment, and available second-line therapies demonstrate low complete response rates of 0-10%. Treatment options are limited, often involving the reuse of older drugs with limited efficacy. The presentation references multiple studies to support these findings and emphasizes the need for improved therapeutic options for this patient population. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligenc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL2s1gy8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2582374285","title":"Immix Biopharma Appoints Michael Grabow as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2582374285","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582374285?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:45","pubTimestamp":1762955121,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on November 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL77NvKV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","JAZZ","IE00BN0W2V16.EUR","BK4533","LU0320765992.SGD","BK4585","LU2095319765.USD","LU2210150020.SGD","IE00BN0W2W23.USD","LU0889565916.HKD","NDAQ","LU0823416689.USD","LU0314104364.USD","IE00BKPKM429.USD","ASRT","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","BK4532","IMMX","LU0109394709.USD","BK4007","IE00B3QW5Z07.USD","BK4112","BK4139"],"gpt_icon":0},{"id":"2582374123","title":"Immix Biopharma Appoints Chief Commercial Officer to Drive Nxc-201 Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2582374123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582374123?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:45","pubTimestamp":1762955100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA3JJLHT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2581837040","title":"Immix Biopharma Inc  expected to post a loss of 17 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581837040","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581837040?lang=en_us&edition=fundamental","pubTime":"2025-11-08 07:52","pubTimestamp":1762559524,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc  expected to post a loss of17cents a share - Earnings Preview Immix Biopharma Inc IMMX.OQ IMMX.O is expected to  report results on November 10 (estimated) for the period ending Dec","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ34C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2580724727","title":"Immix Biopharma Unveils Breakthrough Approach for Relapsed AL Amyloidosis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2580724727","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580724727?lang=en_us&edition=fundamental","pubTime":"2025-11-04 04:42","pubTimestamp":1762202555,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc. has released a presentation highlighting the challenges faced by patients with relapsed or refractory AL amyloidosis in the United States. According to cited sources, approximately 34,000 US patients are affected by this life-threatening condition, which occurs when abnormal antibodies produce toxic light chains that accumulate in organs such as the heart, kidneys, and liver. The presentation outlines the limitations of current treatment options, especially after frontline therapies have failed. It notes that there are no approved drugs for patients with relapsed or refractory AL amyloidosis, and existing second-line therapies yield low complete response rates. The company emphasizes the need for improved therapeutic approaches to address these unmet medical needs. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL3Sq0SC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2580216922","title":"Immix Biopharma to Present Phase 1/2 NXC-201 CAR-T Trial Results for AL Amyloidosis at ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580216922","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580216922?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:45","pubTimestamp":1762177518,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on November 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL5SqtQX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4139","LU2210150020.SGD","IMMX","BK4112","LU2095319765.USD","IE00B3QW5Z07.USD","NDAQ","BK4585","IE00BGHQF748.EUR","BK4588","IE00B64PRP62.GBP","LU0314104364.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2580216940","title":"Immix Biopharma’s Nxc-201 Nexicart-2 Clinical Trial Results Selected for Oral Presentation at Ash 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580216940","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580216940?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:45","pubTimestamp":1762177500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUA43GWNH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2575187402","title":"Immix Biopharma Inc. to Present at Guggenheim Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2575187402","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575187402?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:45","pubTimestamp":1760445908,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc. will present and host institutional investor meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston from November 10-12, 2025. Management will participate in a fireside chat on November 11 at 12:30pm Eastern Time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on October 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL6L6cJd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","BK4588","LU2210150020.SGD","LU2095319765.USD","BK4139","IE00B64PRP62.GBP","IMMX","NDAQ","LU2210149790.SGD","IE00B3QW5Z07.USD","LU0314104364.USD"],"gpt_icon":0},{"id":"2574908721","title":"Immix Biopharma Inc publishes presentation highlighting leadership in relapsed and refractory AL Amyloidosis and promising NXC201 clinical data","url":"https://stock-news.laohu8.com/highlight/detail?id=2574908721","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574908721?lang=en_us&edition=fundamental","pubTime":"2025-10-09 05:49","pubTimestamp":1759960147,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc publishes presentation highlighting leadership in relapsed and refractory AL Amyloidosis and promising NXC201 clinical data. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on October 08, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDL6SDjzL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2573198988","title":"Immix Biopharma to Present Promising NXC-201 Clinical Study Results at 2025 ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2573198988","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573198988?lang=en_us&edition=fundamental","pubTime":"2025-10-07 04:05","pubTimestamp":1759781126,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc. has announced that it will present an abstract on its drug candidate NXC-201 at the upcoming American Society of Hematology  67th Annual Meeting and Exposition. The event is scheduled to take place from December 6-9, 2025, in Orlando, Florida. Details regarding the study or clinical trial results have not yet been disclosed and will be made available at the conference. Immix Biopharma is focused on therapies for relapsed or refractory AL Amyloidosis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on October 06, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL5y52hk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4112","IE00B3QW5Z07.USD","BK4139","LU0314104364.USD","LU2095319765.USD","NDAQ","LU2210149790.SGD","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD","IMMX"],"gpt_icon":0},{"id":"2573672648","title":"Immix Biopharma files to sell 6.85M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2573672648","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573672648?lang=en_us&edition=fundamental","pubTime":"2025-10-06 20:15","pubTimestamp":1759752952,"startTime":"0","endTime":"0","summary":"08:11 EDT Immix Biopharma (IMMX) files to sell 6.85M shares of common stock for holders Published first on TheFly – the ultimate source for real-ti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-files-to-sell-6-85m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-files-to-sell-6-85m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2572316135","title":"Immix Biopharma Inc. to Present and Meet Investors at the 37th Annual Piper Sandler Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2572316135","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572316135?lang=en_us&edition=fundamental","pubTime":"2025-10-01 20:45","pubTimestamp":1759322710,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc., a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, will present and host institutional investor meetings at the 37th Annual Piper Sandler Healthcare Conference, taking place December 2-4, 2025, at the Lotte New York Palace Hotel in New York. A replay of the presentation will be available on the Immix website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on October 01, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL3Hv04C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4127","IE00B64PRP62.GBP","LU0314104364.USD","LU2095319765.USD","LU2210150020.SGD","IE00BKPKM429.USD","BK4588","IMMX","IE00B3QW5Z07.USD","BK4112","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ","PIPR","BK4585"],"gpt_icon":0},{"id":"2568025414","title":"Immix Biopharma Announces 50% Enrollment Milestone Surpassed in Its Ongoing Relapsed/Refractory Al Amyloidosis Clinical Trial, Nexicart-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2568025414","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568025414?lang=en_us&edition=fundamental","pubTime":"2025-09-19 01:30","pubTimestamp":1758216600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250918:nTUABXHJXC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2566597341","title":"Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2566597341","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566597341?lang=en_us&edition=fundamental","pubTime":"2025-09-12 18:45","pubTimestamp":1757673900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 12, 2025 06:45 ET (10:45 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2566994079","title":"Immix Biopharma appoints Nancy Chang to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2566994079","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566994079?lang=en_us&edition=fundamental","pubTime":"2025-09-11 21:35","pubTimestamp":1757597730,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) announced that Nancy Chang, former Tanox CEO, has joined the Immix Biopharma Board of Directors concurrent with her investme...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-appoints-nancy-chang-to-board-of-directors-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-appoints-nancy-chang-to-board-of-directors-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2566996213","title":"Nancy T. Chang, Renowned Biotechnology Leader, Joins Immix Biopharma Board of Directors as Company Strengthens Leadership Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2566996213","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566996213?lang=en_us&edition=fundamental","pubTime":"2025-09-11 21:15","pubTimestamp":1757596522,"startTime":"0","endTime":"0","summary":"Nancy T. Chang, Renowned Biotechnology Leader, Joins Immix Biopharma Board of Directors as Company Strengthens Leadership Team. Los Angeles, CA, Sept. 11, 2025  -- Immix Biopharma, Inc., a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and other serious diseases, announced that Nancy T. Chang has joined its Board of Directors. Dr. Chang, a former CEO of Tanox, Inc., brings extensive experience in biotechnology, having led the development and commercialization of several FDA-approved drugs. Her appointment coincides with her investment as a founding member of Goose Capital.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL8pmLW9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IMMX","LU0314104364.USD","BK4588","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","NDAQ","BK4139","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2095319765.USD","IE00BKPKM429.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":44,"code":"91000000","status":"200"}]}}